Navigation Links
Solazyme Selected for National Institute of Standards and Technology Award
Date:9/27/2007

$2 Million Grant to Support Development of Renewable Replacement for Light

Sweet Crude Oil

SOUTH SAN FRANCISCO, Calif., Sept. 27 /PRNewswire/ -- Solazyme, a bioscience company pioneering biofuels and health/wellness products from microalgae, has received a $2 million Advanced Technology Program Award from the National Institute of Standards and Technology to develop a biopetroleum derived from marine microorganisms.

Under the program, Solazyme will accelerate development of a renewable, domestically produced light sweet crude oil, or biopetroleum, which is fully compatible with the vast existing petroleum industry infrastructure that refines, distributes, and markets petroleum products for transportation, heating, power generation and petrochemical applications. Development of the biopetroleum technology requires efficient industrial scale bioproduction of pure, long-chain hydrocarbons. The ATP award will advance the achievement of major technical milestones toward commercialization of biopetroleum.

"We are pleased to receive external peer reviewed validation of our progress in developing a commercially viable biopetroleum," said Arthur Grossman, chief of genetics for Solazyme, Senior Scientist at the Carnegie Institution, Courtesy Professor at Stanford University and Darbaker prize recipient. "We look forward to advancing this project and adding additional technical expertise to our team as we continue to further the science and the future applications of algal-derived bioenergy."

Solazyme is currently developing biofuels and health/wellness products with microalgae and producing next generation biofuels at the semi-commercial scale. Biopetroleum complements Solazyme's biofuel portfolio, which also includes biodiesel, renewable diesel and renewable (bio)jet fuel and leverages Solazyme's unique expertise in the field of microalgae bioengineering.

"The Advanced Technology Program has historically funded the development of game-changing technologies and we are delighted to be in such esteemed company," added Harrison Dillon, chief executive officer of Solazyme. "The scientific strategy underlying our approach to create biopetroleum will leverage Solazyme's core strengths in the genetic manipulation of microalgae and potentially play a significant role in securing US energy independence."

About Solazyme:

Founded in 2003 and headquartered in South San Francisco, California, Solazyme is a leading biotechnology company focused on the engineering and optimization of algae for production of biofuels and health and wellness materials. For more information, please visit our website: http://www.solazyme.com.

For More Information Contact:

Jackie Kolek Ellen Snook

Peppercom Peppercom

212-931-6166 415-438-9821

jkolek@peppercom.com esnook@peppercom.com


'/>"/>
SOURCE Solazyme
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. San Diego firm selected for Madison Wi-Fi project
2. Milwaukee-based eFilm software selected by InSight Health, announces Workstation upgrade
3. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
4. National Instruments DIAdem -- Complete Your Technical Data Management Framework with Powerful Off-line Analysis, Visualization, and Report Generation
5. Schneider National exec joins TrafficCast board
6. Olympics of biotechnology has international flavor
7. Wisconsin professors elected to National Academy of Sciences
8. CIO Leadership Series: Judy Lemke, Schneider National
9. National angel investment grew 11 percent in `06
10. National broadband policy: Lets get it right this time
11. National Academies induct five UW researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):